Ferguson, James M.

SSRI Antidepressant Medications: Adverse Effects and Tolerability

Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders

Treatment of Major DepressionPsychological Treatments and Disorders

Cited by 669

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 116

An open-label, flexible-dose study of memantine in major depressive disorder

Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 113

Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients

Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 112

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study

Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., et al. (2007) · The Journal of Clinical Psychiatry

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 67